UNLIMITED TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Euronext Paris 10:00:01 17/05/2024 pm IST | ||
| 5.22 EUR | +4.53% |
|
| Current month | +66.83% | ||
| 1 month | +67.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 5.22 | +4.53% |
| 16/24/16 | 4.994 | +1.26% |
| 15/24/15 | 4.932 | +13.25% |
| 14/24/14 | 4.355 | -4.26% |
| 13/24/13 | 4.549 | +6.63% |
Real-time Euronext Paris
Last update May 17, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| EW44S | |
| ISIN | DE000SW1FW56 |
| Date issued | 25/07/2023 |
| Strike | 329.9 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.606 € |
|---|---|
| Lowest since issue | 1.25 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- EW44S Certificat
